1492 Capital Management’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

1492 Capital Management’s Portfolio SYRS Stock Details SYRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-39,244	Closed	-$1.18K	–	129
2025 Q1	$1.18K	Hold	39,244	–	–	﹤0.01%	112
2024 Q4	$9.02K	Hold	39,244	–	–	﹤0.01%	109
2024 Q3	$84.4K	Hold	39,244	–	–	0.04%	100
2024 Q2	$202K	Buy	39,244 +17,500	+80%	+$92K	0.11%	91
2024 Q1	$116K	Hold	21,744	–	–	0.06%	92
2023 Q4	$169K	Hold	21,744	–	–	0.1%	97
2023 Q3	$85.9K	Hold	21,744	–	–	0.06%	91
2023 Q2	$68.5K	Hold	21,744	–	–	0.04%	99
2023 Q1	$58.1K	Hold	21,744	–	–	0.04%	103
2022 Q4	$78.1K	Buy	+21,744	New	+$94.3K	0.05%	100

1492 Capital Management's SYRS Position: Q2 2025 in Review

1492 Capital Management sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q2 2025, closing a stake of 39,244 shares — an estimated $1.18K sold.

1492 Capital Management first reported a position in SYRS in Q4 2022 and held it in 10 quarters. The position peaked at $202K in Q2 2024. 0 funds tracked by Wall St. Rank hold SYRS as of Q2 2025.

1492 Capital Management reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q2 2025 after selling out during the quarter.
1492 Capital Management sold 39,244 Syros Pharmaceuticals, Inc. Common Stock shares in Q2 2025, an estimated $1.18K.
1492 Capital Management first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q4 2022 and held it in 10 quarters.
1492 Capital Management's Syros Pharmaceuticals, Inc. Common Stock position peaked at $202K in Q2 2024.
0 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q2 2025.

Based on 1492 Capital Management's 13F filing for Q2 2025, filed 13 Aug 2025.